🇺🇸 Selective serotonin reuptake inhibitor in United States

32 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Multiple Drug Overdose — 5 reports (15.62%)
  2. Agitation — 4 reports (12.5%)
  3. Death — 4 reports (12.5%)
  4. Serotonin Syndrome — 4 reports (12.5%)
  5. Tachycardia — 4 reports (12.5%)
  6. Toxicity To Various Agents — 3 reports (9.38%)
  7. Brain Injury — 2 reports (6.25%)
  8. Cerebrovascular Accident — 2 reports (6.25%)
  9. Confusional State — 2 reports (6.25%)
  10. Drug Ineffective — 2 reports (6.25%)

Source database →

Selective serotonin reuptake inhibitor in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Selective serotonin reuptake inhibitor approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Selective serotonin reuptake inhibitor in United States?

University of Washington is the originator. The local marketing authorisation holder may differ — check the official source linked above.